Roche Holding stock trades near its 52-week high

Roche Holding stock was trading at CHF 374 on SIX on September 24, 2026, 2.35 percent below its 52-week high of CHF 383. The share price was down 0.32 percent during the session, while the company had a market capitalization of CHF 293,196,644,004.

Stock stays near yearly high

The price comparison gives the current market picture more weight than the small daily move. At CHF 374, Roche Holding remained CHF 9 below the 52-week high of CHF 383, a gap of 2.35 percent based on the same September 24, 2026 market snapshot.

Trading volume stood at 4,015 shares on SIX at the quoted intraday time. The combination of a price near the yearly high and a 0.32 percent decline points to restrained session movement rather than a decisive break of the recent range.

Core earnings set the benchmark

Roche's operating comparison is centered on 2025 core earnings per share. According to Roche, core EPS grew 11 percent at constant exchange rates in 2025 to CHF 19.46 on a diluted basis.

The same investor information records 39 million patients treated with Roche medicines in 2025 and 31 billion diagnostic tests delivered worldwide. Those figures show the scale behind the valuation, while the current market capitalization keeps the stock sensitive to evidence that earnings growth can continue.

Next sales date is October 22

Roche has scheduled its third-quarter sales presentation for October 22, 2026, at 2:00 p.m. CEST, according to Roche. The event is the next dated checkpoint for investors tracking whether the company can convert its 2025 core EPS growth into further sales progress.

Roche Holding stock was trading at CHF 374 on SIX on September 24, 2026. The market capitalization was CHF 293,196,644,004 on the same date, and the 52-week range extended from CHF 264.60 to CHF 383.